Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts. Show more

Location: 400 Fifth Avenue, Waltham, MA, 02451, United States | Website: https://www.ardelyx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

1.074B

52 Wk Range

$3.21 - $7.18

Previous Close

$4.70

Open

$4.66

Volume

4,590,310

Day Range

$4.48 - $4.68

Enterprise Value

905.6M

Cash

214M

Avg Qtr Burn

-11.89M

Insider Ownership

2.51%

Institutional Own.

72.46%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.